Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Cadrenal Therapeutics, Inc. ( (CVKD) ) just unveiled an announcement.
On December 15, 2025, Cadrenal Therapeutics, Inc. entered into a securities purchase agreement for a registered direct offering of 207,374 shares of common stock and unregistered warrants to purchase up to 414,748 shares, aiming to raise approximately $2.2 million. The offering, expected to close on December 16, 2025, includes a lock-up period and restrictions on further stock issuance, impacting the company’s financial strategy and market operations.
The most recent analyst rating on (CVKD) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Cadrenal Therapeutics, Inc. stock, see the CVKD Stock Forecast page.
Spark’s Take on CVKD Stock
According to Spark, TipRanks’ AI Analyst, CVKD is a Underperform.
The overall score reflects significant financial challenges, including ongoing losses and no revenue generation, which weigh heavily on the company’s outlook. Technical indicators suggest limited momentum, while valuation metrics highlight difficulties in assessing the stock’s fair value. Despite a positive corporate development with the appointment of a new Chief Medical Officer, the fundamental financial weaknesses remain the dominant concern.
To see Spark’s full report on CVKD stock, click here.
More about Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. operates in the biopharmaceutical industry, focusing on developing and commercializing therapies for cardiovascular and renal diseases.
Average Trading Volume: 33,142
Technical Sentiment Signal: Sell
Current Market Cap: $22.83M
For detailed information about CVKD stock, go to TipRanks’ Stock Analysis page.